Radiation Therapy, Temozolomide, and Irinotecan in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed newly diagnosed supratentorial glioblastoma multiforme by surgical biopsy or excision
• * No gliomas graded less than glioblastoma multiforme
• * No recurrent malignant gliomas
• No tumor foci below the tentorium or beyond the cranial vault
• Study therapy must begin ≤ 5 weeks after surgery
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• Zubrod 0-1
• Life expectancy
• At least 8 weeks
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 10 g/dL\*
• Hematocrit ≥ 30%\* NOTE: \*Transfusion allowed
• Hepatic
• Bilirubin ≤ 0.5 mg/dL
• ALT or AST ≤ 2 times upper limit of normal
• Renal
• Creatinine ≤ 1.5 mg/dL
• BUN ≤ 25 mg/dL
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective double-barrier contraception during and for 2 months after study participation
• No AIDS
• No other malignancy within the past 5 years except nonmelanoma skin cancer or carcinoma in situ of the cervix or bladder
• No other major medical illness or psychiatric impairment that would preclude study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• No concurrent sargramostim (GM-CSF)
• Chemotherapy
• No other concurrent chemotherapy
• Endocrine therapy
• Concurrent steroid therapy allowed provided patient is on a stable or decreasing dose for at least 2 weeks before study entry
• Radiotherapy
• No prior radiotherapy to the head or neck resulting in overlap of radiotherapy fields
• * Prior radiotherapy for stage T1 glottic cancer allowed
• Surgery
• See Disease Characteristics
• Recovered from prior surgery
• Other
• No enzyme-inducing antiepileptic drugs within 14 days before the initiation of irinotecan
• * Concurrent non-enzyme-inducing antiepileptic drugs allowed